3040 POSTER Optimal dose for an every 2 week (q2w) cetuximab (C) regimen in patients (pts) with metastatic colorectal cancer (mCRC): a phase I safety, pharmacokinetics (PK) and pharmacodynamics (PD) study of weekly (q1w) and q2w schedules

✍ Scribed by F. Ciardiello; A. Cervantes; M. Vega-Villegas; E. Casado; E. Rodriguez-Braun; E. Martinelli; F. Rojo; J. Baselga; O. Kisker; J. Tabernero

• Book ID: 118625810
• Publisher: Elsevier Science
• Year: 2007
• Tongue: English
• Weight: 60 KB
• Volume: 5
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(07)70968-0